Estrella Immunopharma, Inc. - Common Stock Share · US2975841048 · ESLA (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of Estrella Immunopharma, Inc. - Common Stock

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

01.05.2026 20:00

Current Prices from Estrella Immunopharma, Inc. - Common Stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	ESLA	USD	01.05.2026 20:00	1,63 USD	-0,01 USD -0,61 %
IEX	ESLA	USD	01.05.2026 19:59	1,62 USD	-0,02 USD -1,22 %

Share Float & Liquidity

Free Float 39,44 %

Shares Float 16,83 M

Shares Outstanding 42,67 M

Company Profile for Estrella Immunopharma, Inc. - Common Stock Share

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.